Fatty liver and atherogenic dyslipidaemia are major sources of IR-related morbidity, so investigating how these are dissociated from IR in the face of proximal insulin signalling defects will potentially reveal novel approaches to mitigate IR-associated disease. Here, INS is linked to inherited lipid metabolism disorder.